Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
Public ClinicalTrials.gov record NCT00681863. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome
Study identification
- NCT ID
- NCT00681863
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- pramipexole 0.125 mg BID Drug
- pramipexole 0.0625 mg QD Drug
- pramipexole 0.125 mg TID Drug
- pramipexole 0.25 mg BID Drug
- pramipexole 0.0625 mg BID Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Sep 30, 2009
- Completion
- Not listed
- Last update posted
- May 22, 2014
Started 2008
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 248.642.0026 Boehringer Ingelheim Investigational Site | Bradenton | Florida | — | — |
| 248.642.0025 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 248.642.0006 Boehringer Ingelheim Investigational Site | Columbus | Georgia | — | — |
| 248.642.0005 Boehringer Ingelheim Investigational Site | Cambridge | Massachusetts | — | — |
| 248.642.0003 Boehringer Ingelheim Investigational Site | Manhasset | New York | — | — |
| 248.642.0009 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.642.0018 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.642.0013 Boehringer Ingelheim Investigational Site | Orangeburg | New York | — | — |
| 248.642.0029 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 248.642.0010 Boehringer Ingelheim Investigational Site | Providence | Rhode Island | — | — |
| 248.642.0030 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 248.642.0008 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 248.642.0023 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00681863, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00681863 live on ClinicalTrials.gov.